TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LYBALVI

OLANZAPINE
Neurology Approved 2021-05-28
1
Indication
--
Phase 3 Trials
4
Years on Market

Details

Status
Prescription
First Approved
2021-05-28
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: OLANZAPINE , SAMIDORPHAN L-MALATE

LYBALVI Approval History

Loading approval history...

What LYBALVI Treats

3 indications

LYBALVI is approved for 3 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Schizophrenia
  • Bipolar I Disorder
  • Manic Episode
Source: FDA Label

LYBALVI Boxed Warning

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psy...

Drugs Similar to LYBALVI

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ABILIFY ASIMTUFII
ARIPIPRAZOLE
2 shared
OTSUKA
Shared indications:
SchizophreniaBipolar I Disorder
ASENAPINE MALEATE
ASENAPINE MALEATE
2 shared
BRECKENRIDGE
Shared indications:
SchizophreniaBipolar I Disorder
FANAPT
ILOPERIDONE
2 shared
VANDA PHARMS INC
Shared indications:
SchizophreniaBipolar I Disorder
SAPHRIS
ASENAPINE MALEATE
2 shared
AbbVie
Shared indications:
SchizophreniaBipolar I Disorder
ZYPREXA
OLANZAPINE
2 shared
CHEPLAPHARM
Shared indications:
SchizophreniaBipolar I Disorder
ZYPREXA ZYDIS
OLANZAPINE
2 shared
CHEPLAPHARM
Shared indications:
SchizophreniaBipolar I Disorder
ABILIFY MAINTENA KIT
ARIPIPRAZOLE
1 shared
OTSUKA PHARM CO LTD
Shared indications:
Schizophrenia
ADASUVE
LOXAPINE
1 shared
NOVA PNEUMA
Shared indications:
Schizophrenia
ARIPIPRAZOLE
ARIPIPRAZOLE
1 shared
UNICHEM
Shared indications:
Schizophrenia
ARISTADA
ARIPIPRAZOLE LAUROXIL
1 shared
ALKERMES INC
Shared indications:
Schizophrenia
ARISTADA INITIO KIT
ARIPIPRAZOLE LAUROXIL
1 shared
ALKERMES INC
Shared indications:
Schizophrenia
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
Schizophrenia
COBENFY
TROSPIUM CHLORIDE
1 shared
Bristol-Myers Squibb
Shared indications:
Schizophrenia
ERZOFRI
PALIPERIDONE PALMITATE
1 shared
LUYE INNOMIND PHARMA
Shared indications:
Schizophrenia
FLUPHENAZINE DECANOATE
FLUPHENAZINE DECANOATE
1 shared
PH HEALTH
Shared indications:
Schizophrenia
HALOPERIDOL DECANOATE
HALOPERIDOL DECANOATE
1 shared
MANKIND PHARMA
Shared indications:
Schizophrenia
IGALMI
DEXMEDETOMIDINE HYDROCHLORIDE
1 shared
BIOXCEL
Shared indications:
Schizophrenia
INVEGA HAFYERA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
INVEGA SUSTENNA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
INVEGA TRINZA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LYBALVI FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment

⚠️ BOXED WARNING

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis [see Warnings an...

LYBALVI Patents & Exclusivity

Latest Patent: Nov 2041
Exclusivity: May 2026

Patents (336 active)

US11951111 Expires Nov 12, 2041
US12390474 Expires Nov 12, 2041
US11707466 Expires Nov 12, 2041
US10300054 Expires May 31, 2033
US8778960 Expires Feb 13, 2032
US9119848 Expires Aug 30, 2031
US11241425 Expires Aug 23, 2031
US12194035 Expires Aug 23, 2031
US11185541 Expires Aug 23, 2031
US11793805 Expires Aug 23, 2031
+ 326 more patents

Exclusivity

NCE Until May 2026
NCE Until May 2026
NCE Until May 2026
NCE Until May 2026
NCE Until May 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.